Endometriosis therapy with medroxyprogesterone acetate
Non-randomised trial
OA: closed
CC0
⤵ 15 in-corpus citations
AI-generated summary
Medroxyprogesterone acetate (MPA) therapy for 90 days provided symptomatic relief and improved healing in patients with endometriosis, causing ovulatory suppression and minimal side effects.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Use of orally administered medroxyprogesterone acetate (MPA) 10 mg 3 times a day for 90 days was undertaken to assess its effect in patients with endometriosis. Subjects were 24 patients with symptoms of premenstrual pain suggestive of endometriosis. No patient had a large palpable adnexal mass. Patient interviews and pelvic and breast examinations were done before treatment at 30-day intervals during treatment and 30 days after treatment. Routine hematology urinalysis and blood chemistries were evaluated at the same periods. Endoscopic examinations were done before treatment and after 90 days of MPA therapy. Plasma progesterone was measured by radioimmunoassay at 2-week intervals during treatment and for 4 weeks after treatment. Endometrial biopsies were done in the pretreatment cycle and again on the last day of treatment. Symptomatic relief was total in 24 cases and improved in 3. In 1 case premenstrual pain recurred 11 months after treatment. Of 22 patients who had follow-up endoscopy examinations 15 had complete healing and 7 showed improvement. Plasma progesterone values showed ovulatory suppression during therapy and prompt restoration of ovulatory function later. Other examinations showed no significant changes. There were not drug-related side effects except occasional spotting. The MPA therapy was considered as somtimes palliative only but effective and preferable to other forms of medical management of endometriosis.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
Cited by (15)
- Current understanding on pharmacokinetics, clinical efficacy and safety of progestins for treating pain associated to endometriosis 2018
- Current pharmacotherapy for endometriosis 2010
- The role of progestins in treating the pain of endometriosis 2006
- Current place of progestins in the treatment of endometriosis-related complaints 2001
- Changes in quality of life after hormonal treatment of endometriosis 2001
- Effects of dienogest (a synthetic steroid) on coagulation, fibrinolysis, and platelet aggregation in female monkeys 1998
- Progestins for symptomatic endometriosis: a critical analysis of the evidence 1997
- Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis 1996
- Endometriosis and pelvic pain 1993
- Endometriosis: medical therapy 1993
- Principles of medical therapy for endometriosis pain 1992
- Endometriosis—the role of medroxyprogesterone acetate 1992
- Gestogens and anti-gestogens as treatment of endometriosis 1991
- Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis 1987
- Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis after conservative surgery 1987
Source provenance
- europepmc
- last seen: 2026-10-15T06:08:49.021275+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-10-08T22:00:48.437354+00:00
License: CC0
· commercial use OK